SCHEMBL2292004

SCHEMBL2292004

Cc1cccc(C)c1Nc1c(-c2ccccc2OCC(N)=O)nc2c(F)cccn12

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 9/20 0.46
MAPT P10636 8/20 0.46
TP53 P04637 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
KCNN4 O15554 2/20 0.42
ADORA1 P30542 1/20 0.38
LMNA P02545 3/20 0.38
HTT P42858 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TDP1 Q9NUW8 1/20 0.36
PDE5A O76074 1/20 0.36
GUCY1B2 O75343 3/20 0.36
GUCY1A2 P33402 3/20 0.36
GUCY1A1 Q02108 3/20 0.36
GUCY1B1 Q02153 3/20 0.36
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2289678 0.93 GAA (0.54) GAAMAPTTP53SMN1; SMN2ADORA1
SCHEMBL2287261 0.91 MAPT (0.45) GAAMAPTTP53SMN1; SMN2KCNN4
SCHEMBL2296118 0.88 MAPT (0.43) GAAMAPTTP53SMN1; SMN2LMNA
SCHEMBL2287284 0.88 KCNN4 (0.39) GAAMAPTTP53SMN1; SMN2KCNN4
SCHEMBL2288504 0.85 GAA (0.54) GAAMAPTTP53SMN1; SMN2LMNA
SCHEMBL2810374 0.83 GAA (0.66) GAAMAPTTP53SMN1; SMN2LMNA
SCHEMBL2287280 0.83 MAPT (0.45) GAAMAPTTP53SMN1; SMN2KCNN4
SCHEMBL2287174 0.83 GAA (0.44) GAAMAPTTP53SMN1; SMN2KCNN4
SCHEMBL2288909 0.80 GAA (0.49) GAAMAPTTP53SMN1; SMN2LMNA
SCHEMBL2290324 0.80 GAA (0.49) GAAMAPTTP53SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP claimed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US claimed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 GAA 1202/4885MAPT 1138/4885TP53 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.